PanXome is software technology company with a platform which enables a broader spectrum of drug discovery than conventional computer-aided drug discovery tools. The platform is grounded in a unique approach to which combines artificial intelligence with predictive models of druggable protein targets, based on homology and ligand similarity. The platform is computationally efficient and covers 97% of the human exome, which opens a heretofore inaccessible region of target exploration and the ability to predict off-target interactions. PanXome provides the following services on a fee-for-service basis:

> Target Identification – Identify target for existing compound or for a specific disease.
> Virtual Ligand Screening (VLS) – Screen proprietary or public libraries for binding to a specific protein.
> Off-target Interactions – De-risk molecule by predicting side effects and specific proteins causing the side effect.
> Repurposing – Find alternative indications for an existing drug.
> QSAR – Refinement for better binding affinity and designing away from proteins causing an unwanted side effect.

PanXome is open to collaborations.